
FDA Approves Drug That Doubles Lifespan for Pancreatic Cancer Patients
The story in brief
The FDA approved daraxonrasib, a drug that doubles lifespan for late-stage pancreatic cancer patients, based on phase 3 trial results. A 70-year-old man, who had cancer spread to his lymph nodes in 2022, is now alive with tumors no longer visible in scans. The trial showed survival from 7 to over 13 months, with only 3% surviving beyond five years. KRAS-inhibiting drugs are now being tested for other cancers like colon and lung.